Discovery of primary prostate cancer biomarkers using cross cancer learning
Abstract Prostate cancer (PCa), the second leading cause of cancer death in American men, is a relatively slow-growing malignancy with multiple early treatment options. Yet, a significant number of low-risk PCa patients are over-diagnosed and over-treated with significant and long-term quality of li...
Main Authors: | Kaiyue Zhou, Suzan Arslanturk, Douglas B. Craig, Elisabeth Heath, Sorin Draghici |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-89789-x |
Similar Items
-
Unveiling genetic variant-level biomarkers for aggressive prostate cancer
by: Tasnimul Alam Taz, et al.
Published: (2023-01-01) -
Biomarker-driven drug repurposing on biologically similar cancers with DNA-repair deficiencies
by: Seeya Awadhut Munj, et al.
Published: (2022-12-01) -
Integration of Multimodal Data from Disparate Sources for Identifying Disease Subtypes
by: Kaiyue Zhou, et al.
Published: (2022-02-01) -
The proteomics in prostate cancer biomarker discovery
by: V. E. Shevchenko, et al.
Published: (2015-06-01) -
Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
by: Nuria Gómez-Cebrián, et al.
Published: (2019-03-01)